Status:
TERMINATED
n3 PUFA and Muscle-disuse Atrophy in Older Women
Lead Sponsor:
McMaster University
Conditions:
Muscle Atrophy
Muscle Disuse Atrophy
Eligibility:
FEMALE
55-75 years
Phase:
NA
Brief Summary
This study will examine the influence of n3 PUFA supplementation on the rate of muscle atrophy in older women undergoing 1 week of unilateral limb immobilization. Assessments in skeletal muscle streng...
Detailed Description
Biological aging is associated with the loss of skeletal muscle mass and strength resulting in compromised metabolic function and mobility. Throughout life, individuals will also experience periods of...
Eligibility Criteria
Inclusion
- Female
- Aged 55 - 75 years old
- non-smoking (for at least 2 years)
- \> 5 years post-menopausal
- Body mass index (BMI) between 22 and 33 kg/m2
- Mini-Mental State Exam (MMSE) score \> 20
- Acceptable medications include: Angiotensin Converting Enzyme (ACE), Beta-Blockers, Acetylsalicylic Acid, Calcium Channel blockers, Depression/Anxiety meds, Bisphosphonates (Fosamax®, Didrocal®, Actonel®, Aclasta®).
Exclusion
- Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigators, would compromise the ability to comply with the study requirements.
- History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer, or carcinoma in situ with no significant progression over the past 2 years.
- Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude oral n-3 PUFA supplement ingestion and/or assessment of safety and study objectives
- Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing)
- Participation in a study of an investigational product less than 60 days or 5 half-lives of the investigational product, whichever is longer, before enrollment in this study
- Hypersensitivity to the test product
- Excessive alcohol consumption (\>21 units/week)
- Prior gastrointestinal bypass surgery
- History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy
- Personal or family history of clotting disorder or deep vein thrombosis
- Concomitant use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), or any anabolic steroid
Key Trial Info
Start Date :
February 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03808519
Start Date
February 18 2019
End Date
July 1 2021
Last Update
October 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Exercise Metabolism Research Laboratory, McMaster Univeristy
Hamilton, Ontario, Canada, L8S 4K1